AHA: Cannabis May Have Adverse Cardiovascular Effects
No indication of cardiovascular benefits found; more research needed to further understand adverse effects.
CHF and Arrhythmias
Empagliflozin Heart Failure Study Meets Primary End Point
The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes.
FDA to Review Furosemide Formulation Delivered Via On-Body Infusor
Furoscix is an investigational, proprietary, pH-neutral formulation of furosemide designed for subcutaneous administration via a wearable, pre-programmed on-body drug delivery system for outpatient self-administration.
Mavacamten Gets Breakthrough Therapy Status for Obstructive Hypertrophic Cardiomyopathy
The designation is supported by results from the phase 3 EXPLORER-HCM trial that evaluated mavacamten in 251 adult patients with symptomatic, obstructive HCM.
High Prevalence of Americans Have Conditions Linked to Severe COVID-19
Median prevalence of any underlying medical condition 47.2% for residents in all 50 states, DC.
Spironolactone Use Associated With Reduced Prostate Cancer Risk
Men who had ever used spironolactone had decreased odds of prostate cancer compared with never-users, according to a study.
Dapagliflozin Fast-Tracked for Heart Failure Following Acute MI
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) to reduce the risk of hospitalization for heart failure or cardiovascular (CV) death in adults following an acute myocardial infarction.
Vericiguat Gets Priority Review for Heart Failure With Reduced Ejection Fraction
The FDA has accepted for Priority Review the New Drug Application for vericiguat to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction.
Sacubitril/Valsartan Under Review for Heart Failure With Preserved Ejection Fraction
The FDA has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsartan (Entresto; Novartis) in the treatment of heart failure with preserved ejection fraction.
Daily Coffee May Lower Risk for Developing Arrhythmia
Each additional cup tied to further decrease in arrhythmia risk.
